{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:03:42Z","timestamp":1790935422210,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The dose-dependent effect of ibandronate treatment on bone mass and architecture was assessed in a large animal study of OVX monkeys using \u03bcCT for quantitative bone morphometry and biomechanical testing for measures of bone strength. The study showed that intermittent ibandronate preserved lumbar spine bone quality and strength in these animals after 16 months of treatment.<\/jats:p>\n               <jats:p>Introduction: Ibandronate is a bisphosphonate, which is a class of compounds that, in pharmacologically active doses, not only suppresses bone resorption and turnover but also prevents loss of bone mass and strength in the ovariectomized (OVX) rat.<\/jats:p>\n               <jats:p>Materials and Methods: We evaluated the effects of ibandronate on bone mass and architecture in the OVX cynomolgus macaque. Sixty-one adult female macaques were divided into five groups (N = 11\u201315): sham control, OVX control, and OVX low- (10 \u03bcg\/kg), medium- (30 \u03bcg\/kg), and high- (150 \u03bcg\/kg) dose ibandronate. Treatment was administered by intravenous bolus injection every 30 days for 16 months starting at ovariectomy. This dosing schedule is equivalent to a 3-monthly dosing regimen in human subjects over 4 years. Animals were killed at the conclusion of the study, and excised bone specimens of the first lumbar vertebra (L1) were evaluated for quantitative bone densitometry, morphometry, and mechanical properties. Architectural parameters were assessed by \u03bcCT including direct 3D bone morphometry. A measure of specimen strength was obtained using destructive compression testing.<\/jats:p>\n               <jats:p>Results and Conclusions: A significant loss of bone mass and related changes in bone architecture after ovariectomy resulted in a reduction of whole bone strength as expressed by high correlations between architectural and mechanical properties. In this analysis, BMC was the best single predictor of whole bone strength (r2 = 67%). Nevertheless, including architectural indices in a multiple linear regression analysis increased that prediction to 88%. With respect to the treatment, the medium- and high-dose groups were not significantly different from the sham group for all bone mineral and structural parameters. Additionally, significant differences were seen for all measured parameters between the high-dose group and the OVX group, and for some parameters, between the medium-dose group and the OVX group. Intermittent ibandronate treatment effectively and dose-dependently prevented bone loss, architectural deterioration, and strength reduction in the lumbar spine of OVX monkeys.<\/jats:p>","DOI":"10.1359\/jbmr.040809","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T23:27:15Z","timestamp":1146094035000},"page":"1787-1796","source":"Crossref","is-referenced-by-count":81,"title":["Intermittent Ibandronate Preserves Bone Quality and Bone Strength in the Lumbar Spine After 16 Months of Treatment in the Ovariectomized Cynomolgus Monkey"],"prefix":"10.1093","volume":"19","author":[{"given":"Ralph","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hannan","sequence":"additional","affiliation":[{"name":"Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Y","family":"Smith","sequence":"additional","affiliation":[{"name":"Bone Research, Pathology Division, CTBR Bio-Research Inc., Senneville, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frieder","family":"Bauss","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Heidelberg University, Mannheim, Germany"},{"name":"Roche Diagnostics GmbH, Pharma Research-Bone Metabolism, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013107473320200_bib1","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1172\/JCI116872","article-title":"The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates","volume":"92","author":"Balena","year":"1993","journal-title":"J Clin Invest"},{"key":"2024013107473320200_bib2","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1359\/jbmr.1998.13.11.1775","article-title":"Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys","volume":"13","author":"Binkley","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024013107473320200_bib3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024013107473320200_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02672503","article-title":"Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats","volume":"8","author":"Lalla","year":"1998","journal-title":"Osteoporos Int"},{"key":"2024013107473320200_bib5","first-page":"990","article-title":"Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"2024013107473320200_bib6","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"2024013107473320200_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/jbmr.5650081109","article-title":"A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs","volume":"8","author":"Monier-Faugere","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024013107473320200_bib8","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1359\/jbmr.1999.14.10.1768","article-title":"Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties","volume":"14","author":"Monier-Faugere","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024013107473320200_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone"},{"key":"2024013107473320200_bib10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int"},{"key":"2024013107473320200_bib11","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jbmr.5650091115","article-title":"Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage","volume":"9","author":"Bikle","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024013107473320200_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF01320915","article-title":"Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties","volume":"53","author":"Guy","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2024013107473320200_bib13","first-page":"128","article-title":"Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: Comparison with pamidronate and etidronate in growing rats","volume":"286","author":"Azuma","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2024013107473320200_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1742-1241.2003.tb10518.x","article-title":"Ibandronate: A potent new bisphosphonate in the management of postmenopausal osteoporosis","volume":"57","author":"Papapoulos","year":"2003","journal-title":"Int J Clin Pract"},{"key":"2024013107473320200_bib15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1358\/dot.2003.39.11.799465","article-title":"Ibandronate: New options in the treatment of osteoporosis","volume":"39","author":"Adami","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"2024013107473320200_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0149-2918(03)90005-1","article-title":"Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: A review of three phase II studies","volume":"25","author":"Schimmer","year":"2003","journal-title":"Clin Ther"},{"key":"2024013107473320200_bib17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013107473320200_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"2024013107473320200_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thiebaud","year":"1997","journal-title":"Am J Med"},{"key":"2024013107473320200_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","article-title":"Intravenous ibandronate injections given every three months: A new treatment option to prevent bone loss in postmenopausal women","volume":"62","author":"Stakkestad","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2024013107473320200_bib21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"2024013107473320200_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/07853899708998743","article-title":"Bisphosphonates: Preclinical aspects and use in osteoporosis","volume":"29","author":"Fleisch","year":"1997","journal-title":"Ann Med"},{"issue":"Suppl 4","key":"2024013107473320200_bib23","doi-asserted-by":"crossref","first-page":"297S","DOI":"10.1016\/8756-3282(95)00307-Y","article-title":"Animal models of cortical porosity","volume":"17","author":"Sietsema","year":"1995","journal-title":"Bone"},{"key":"2024013107473320200_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s001980050161","article-title":"Importance of preclinical studies in the development of drugs for treatment of osteoporosis: A review related to the 1998 WHO guidelines","volume":"9","author":"Bonjour","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024013107473320200_bib25","volume-title":"Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis","author":"World","year":"1998"},{"key":"2024013107473320200_bib26","author":"Committee for Proprietary Medicinal Products","year":"2001"},{"key":"2024013107473320200_bib27","author":"Food and Drug Administration","year":"1994"},{"key":"2024013107473320200_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/8756-3282(93)90169-B","article-title":"The long-term effect of ovariectomy on the quality and quantity of cortical bone in the young cynomolgus monkey: A comparison of density fractionation and histomorphometric techniques","volume":"14","author":"Lundon","year":"1993","journal-title":"Bone"},{"key":"2024013107473320200_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF02509542","article-title":"A microtomographic system for the nondestructive evaluation of bone architecture","volume":"58","author":"R\u00fcegsegger","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2024013107473320200_bib30","first-page":"61","article-title":"Micro-tomographic imaging for the nondestructive evaluation of trabecular bone architecture","volume":"40","author":"M\u00fcller","year":"1997","journal-title":"Stud Health Tech Inform"},{"key":"2024013107473320200_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1088\/0031-9155\/39\/1\/009","article-title":"Non-invasive bone biopsy: A new method to analyse and display the three-dimensional structure of trabecular bone","volume":"39","author":"M\u00fcller","year":"1994","journal-title":"Phys Med Biol"},{"key":"2024013107473320200_bib32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1359\/jbmr.1999.14.7.1167","article-title":"Direct three-dimensional morphometric analysis of human cancellous bone: Microstructural data from spine, femur, iliac crest, and calcaneus","volume":"14","author":"Hildebrand","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024013107473320200_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/BF00540446","article-title":"Characterization of microstructural anisotropy in orthotropic materials using a second rank tensor","volume":"19","author":"Harrigan","year":"1984","journal-title":"J Mater Sci"},{"key":"2024013107473320200_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0021-9290(94)90014-0","article-title":"The relationship between the structural and orthogonal compressive properties of trabecular bone","volume":"27","author":"Goulet","year":"1994","journal-title":"J Biomech"},{"key":"2024013107473320200_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/8756-3282(92)90078-B","article-title":"Trabecular bone pattern factor\u2014a new parameter for simple quantification of bone microarchitecture","volume":"13","author":"Hahn","year":"1992","journal-title":"Bone"},{"key":"2024013107473320200_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/01495739708936692","article-title":"Quantification of bone microarchitecture with the structure model index","volume":"1","author":"Hildebrand","year":"1997","journal-title":"Comput Methods Biomech Biomed Engin"},{"key":"2024013107473320200_bib37","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2002.17.7.1139","article-title":"Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography","volume":"17","author":"Borah","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013107473320200_bib38","first-page":"1","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"17","author":"Consensus Development Conference","year":"2000","journal-title":"NIH Consens State Sci Statements"},{"key":"2024013107473320200_bib39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJM199208273270908","article-title":"The prevention and treatment of osteoporosis","volume":"327","author":"Riggs","year":"1992","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.040809","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/11\/1787\/56474990\/5650191106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/11\/1787\/56474990\/5650191106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:07:16Z","timestamp":1710342436000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/19\/11\/1787-1796\/7592813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.040809","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,11,1]]},"published":{"date-parts":[[2004,11,1]]}}}